Table S1. Mouse models with human skin graft.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Paper** | **MODEL** | **MOUSE STRAIN** | **HUMAN SKIN GRAFT SIZE (cm2)** | **HUMAN SKIN GRAFT THICKNESS** | **FOLLOW-UP of the skin graft (days)** | **APPLICATION** |
| 1 | Lance and Medawar (1968) | CBA mice treated with antilymphocytic serum | 1 | STSG | 60 | Immunology |
| 2 | Pass et al. (1973) | C57BL/6J | 0.4 - 1 | STSG | 240 | Skin diseases |
| 3 | Reed and Manning (1973) | BALB/c nude | 1 | FTSG | 103 | Immunology |
| 4 | Krueger et al. (1975) | BALB/c nu/nu | 0.6 | STSG | 77 | Skin diseases |
| 5 | Cubie (1976) | Nude | 0.25 | STSG | 100 | Skin diseases |
| 6 | Briggaman et al. (1976) | NMRI/BOM-nu/nu | 0.4 - 0.6 | STSG | 120 | Skin diseases |
| 7 | Yuspa et al. (1979) | Nude (nu/nu) | 1 | FTSG | 189 | Carcinogenesis |
| 8 | Haftek et al. (1981) | Balb/C nu/nu | 0.4 | STSG | 30 | Skin diseases |
| 9 | Krueger et al. (1983) | Balb/C nu (H-2d | NA | STSG | 63 | Physiology and Pharmacology |
| 10 | Reifenrath et al. (1984) | Balb/C nu/nu | NA | STSG | 42 | Physiology and Pharmacology |
| 11 | Petersen et al. (1984) | CD-1 outbred nude | 2.25 | FTSG | 84 | Physiology and Pharmacology |
| 12 | Gross et al. (1985) | Balb/C nu/nu | 0.6 - 1.4 | STSG | 49 | Physiology and Pharmacology |
| 13 | Shetlar et al. (1985) | Nude (Nu/cox) | 0.25 - 1 | NA | 60 | Wound Healing and Scarring |
| 14 | Demarchez et. al (1986) | Nude (Swiss nu/nu) | 1 | STSG | 119 | Wound Healing and Scarring |
| 15 | Van Genderen et al. (1985) | Athymic nude | 3.14 | STSG | 180 | Physiology and Pharmacology |
| 16 | Robertson et al. (1986) | N:NIH(S)-nu | 1 - 3 | FTSG | 245 | Physiology and Pharmacology |
| 17 | McGown et al. (1987) | Athymic nude | 0.6 - 1.4 | STSG | 35 | Physiology and Pharmacology |
| 18 | Robb et al. (1987) | Nude | NA | FTSG | 180 | Wound Healing and Scarring |
| 19 | Yohn et al. (1988) | Nude (nu/nu NIH-Swiss) | 0.6 | FTSG | 28 | Carcinogenesis |
| 20 | Klain (1989) | Athymic nude | NA | STSG | 42 | Physiology and Pharmacology |
| 21 | Gilhar et al. (1989/1991) | Balb/C nude | 4 | STSG | 70 | Skin diseases |
| 22 | Kischer et al. (1989) | Nude (nu/nu) | 0.4 | STSG | 246 | Wound Healing and Scarring |
| 23 | Charley et al. (1990) | C.B17 SCID | 0.3 | STSG | 30 | Carcinogenesis |
| 24 | Kanitakis et al. (1990) | Swiss nu/nu | 1 | STSG | 35 | Physiology and Pharmacology |
| 25 | Lorenz et al. (1992) | Nude (nu/nu) | 0.25 | FTSG | 28 | Wound Healing and Scarring |
| 26 | Kim et al. (1992) | SCID | 2.1 | FTSG | 168 | Skin diseases |
| 27 | Yan et al. (1993) | SCID | 2.25 (2 skin grafts per animal) | FTSG | 56 | Physiology and Pharmacology |
| 28 | Juhasz et al. (1993) | - Balb/c nu/nu  - SCID | 1.5 | FTSG | 120 | Carcinogenesis |
| 29 | Wu et al. (1993) | Swiss | 3 - 5 | STSG | 36 | Immunology |
| 30 | Kaufmann et al. (1993) | C.B17 SCID | 1.2 | STSG | 365 | Physiology and Pharmacology |
| 31 | Otulakowski et al. (1994) | Balb/C | 1 | FTSG | 28 | Physiology and Pharmacology |
| 32 | Jánossy et al. (1994) | - A/J  - CBA/Ca | NA | STSG | 120 | Immunology |
| 33 | Murray et al. (1994) | C.B-17 SCID | 0.5 | STSG | 30 | Immunology |
| 34 | Alegre et al. (1994) | CB17 scid/scid H-2d | NA | NA | 365 | Immunology |
| 35 | Ueda et al. (1994) | Nude | 0.25 | NA | 14 | Skin diseases |
| 36 | Boehncke et al. (1994) | C.B17 SCID | 0.6 - 1 | FTSG | 42 | Skin diseases |
| 37 | Urano et al. (1995) | CB-17 SCID | 1 - 2 | FTSG and STSG | 180 | Carcinogenesis |
| 38 | Hoefakker et al. (1995) | BALB/c-nu/nu | 1 | FTSG | 63 | Immunology |
| 39 | Nickoloff et al. (1995) | SCID | 2.25 | FTSG | 42 | Skin diseases |
| 40 | Soballe et al. (1996) | CB17 SCID | 3 - 5 | FTSG | 330 | Carcinogenesis |
| 41 | Young et al. (1996) | BALB/c-nu/nu | 1.5 | STSG | 28 | Physiology and Pharmacology |
| 42 | Petzelbauer et al. (1996) | C.B17 SCID | 1 | STSG | 14 | Physiology and Pharmacology |
| 43 | Paslin et al. (1997) | -C.B17 SCID  -NOD/LtSz-scid  -129 J-nu/nu  -N III- nu/nu | NA | NA | 133 - 280 | Skin diseases |
| 44 | Takizawa et al. (1997) | -SCID  -BALB/cA-nude-scid  -BALB/cA- beige-scid | 1 | NA | 233 | Skin diseases |
| 45 | Nomura et al. (1997) | C.Bl7-scid/scid | 1.5 | NA | 800 | Carcinogenesis |
| 46 | Tsuchida et al. (1997) | CB-17 scid/scid | NA | NA | 28 | Immunology |
| 47 | Atillasoy et al. (1997) | RAG-1 | 1 - 3 | FTSG | 300 | Carcinogenesis |
| 48 | Rosenblatt-Velin et al. (1997) | C.B17 SCID | 1.5 | STSG | 14-28 | Physiology and Pharmacology |
| 49 | Sugai et al. (1998) | CB-17 SCID | 2 - 3 | STSG | 154 | Skin diseases |
| 50 | White et al. (1999) | CBA/nu | 0.6 | FTSG | 42 | Physiology and Pharmacology |
| 51 | Moulton et al. (1999) | SCID | 1 | NA | 56 | Immunology |
| 52 | Uchida et al. (1999) | -C57BL/6 CrSlc  - CD 4 knockout  - CD 8 knockout  - C3H/He Slc | 1 | FTSG | 100 | Immunology |
| 53 | Lazarova et al. (2000) | SCID | 6 | FTSG | 150 | Skin diseases |
| 54 | Zillikens et al. (2001) | SCID | 2 | FTSG | 21 -28 | Skin diseases |
| 55 | Coates et al. (2001) | NOD-SCID | NA | STSG | 100 | Immunology |
| 56 | Yamanaka et al. (2001) | CB-17 SCID | 1 | NA | 28 | Skin diseases |
| 57 | Zeigler et al. (2001) | CB-17 SCID | 1 | FTSG | 49 | Skin diseases |
| 58 | Berking et al. (2002) | -CB17 SCID  -B6,129S-Rag-1tm1Mom | 1 - 3 | FTSG | 300 | Carcinogenesis |
| 59 | Erdag et al. (2002) | CB-17 SCID | 1 | FTSG | 70 | Immunology |
| 60 | Carballido et al. (2003) | C.B-17/GbmsTac-Prkdcscid Lystbg | 1 | FTSG | 49-63 | Physiology and Pharmacology |
| 61 | Moscicka et al. (2003) | CB-17 SCID | 1 | NA | 21 | Physiology and Pharmacology |
| 62 | Turgeon et al. (2003) | NOD/LtSz-*Prkdcscid/Prkdcscid B2mnull* | NA | FTSG | 36 | Immunology |
| 63 | Zone et al. (2004) | -Athymic  -C.B17-SCID | NA | NA | 35 | Skin diseases |
| 64 | Kappes et al. (2004) | SCID | 1.2 | STSG | 180 | Physiology and Pharmacology |
| 65 | Boyman et al. (2004) | AGR 129 | NA | STSG | 56 | Skin diseases |
| 66 | Ullrich et al. (2004) | Pfp-/-Rag2-/- | 0.25 | STSG | 21 -28 | Skin diseases |
| 67 | Capt et al (2007) | Swiss *nu*/*nu* | 1 | STSG | 56 | Physiology and Pharmacology |
| 68 | Yang et al. (2007) | Nude (BALB/c-nu/nu) | 3 | FTSG | 180 | Wound Healing and Scarring |
| 69 | Fairley et al. (2007) | Nude (nu/nu) | 4 | NA | 14 | Skin diseases |
| 70 | Rissin et al. (2009) | Nude | Micrografts onto 1.5 cm2 bed | STSG | 11 | Wound Healing and Scarring |
| 71 | Racki et al. (2010) | -SCID.beige  -BALB/c-scid  -BALB/c-Rag1null IL2rɣnull  -NOD-Rag1null  -NOD-Rag1nullPrf1null  -NSG | 1 - 1.5 | STSG | 70 | Immunology |
| 72 | Gaucher et al. (2010) | BALB/c | 0,6 | STSG | 22 | Wound Healing and Scarring |
| 73 | Issa et al. (2010) | BALB/cRag2−/−; Il2rγ−/− (H2d) | 1 | STSG | 100 | Immunology |
| 74 | Wang et al. (2011) | Nude (BALB/c-nu/nu) | 3 | FTSG and STSG | 210 | Wound Healing and Scarring |
| 75 | Sagoo et al. (2011) | -NSG  -BALB/cRag2−/− γc−/− | 1 | STSG | 84 | Immunology |
| 76 | Kang and Shen (2012) | BALB/c-nu/nu | 1 | FTSG | 28 | Physiology and Pharmacology |
| 77 | Guo et al. (2012) | Athymic | 4 | FTSG | 70 | Wound Healing and Scarring |
| 78 | Mihara et al. (2012) | BNX | NA | FTSG | 42 | Skin diseases |
| 79 | De Oliveira et al. (2012) | SCID/beige | NA | STSG | 42 | Immunology |
| 80 | Philandrianos et al. (2012) | Nude (nu/nu) | 0.6 | NA | 112 | Wound Healing and Scarring |
| 81 | Melican et al. (2013 | SCID/beige | 2 | STSG | 28 | Skin diseases |
| 82 | Staunstrup et al. (2013 | C.B-17 SCID | 2.25 | STSG | 17 | Physiology and Pharmacology |
| 83 | Makino et al. (2014 | Nude (KSN/Slc) | 1 | NA | 60 | Physiology and Pharmacology |
| 84 | Soria et al. (2014) | NSG | 1 | FTSG | 28 | Physiology and Pharmacology |
| 85 | Maldonado et al. (2014) | NOD.CB17-Prkdcscid/NCrHsd | 12 | FTSG | 190 | Wound Healing and Scarring |
| 86 | Shanmugam et al. (2015) | Nude (nu/nu) | 1.4 | FTSG | 90 | Wound Healing and Scarring |
| 87 | Alrobaiea et al. (2016) | Athymic nude | 4.5 | FTSG | 90 - 365 | Wound Healing and Scarring |
| 88 | Zhou et al. (2017) | Nude (nu/nu Balb/c) | 3.2 - 4 | NA | 56 | Wound Healing and Scarring |
| 89 | Zerboni et al. (2018) | C.B-17 SCID  NOD.Cg-*PrkdcscidIl2rgtm1Sug*/JicTac (NOG) | 0.6 | STSG | 59 | Skin diseases |
| 90 | Ghraieb et al. (2018) | Beige-SCID  NSG | 0.1 | FTSG | 75 | Skin diseases |
| 91 | Quantin et al. (2020) | Nude | 2 | FTSG | 34 | Physiology and Pharmacology |

**LEGEND:**

*NA:* not available

*STSG:* split thickness skin graft

*FTSG:* full thickness skin graft

*SCID*: severe combined immune deficiency

*NOD:* nonobese diabetic

*BNX:* beige, nude, xid

*NSG mice:* NOD*-scid IL2r*γ*null*

*SCID.beige:* CB17.B6-*Prkdcscid Lystbg*/Crl

*RAG:* Recombination-activating gene 1 – deficient mice